Are SPACs Good Or Bad For Biopharma?

Special Purpose Acquisition Companies (SPACs) homed in on the biopharma industry in 2020, providing biotech companies with a faster and looser route to the public market. Is there a downside?

up and down arrows

More from Business Strategy

More from In Vivo